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Predicting Beneﬁt From CRT
When Is it Too Little, Too Late?*
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tCardiac resynchronization therapy (CRT) is a stan-
dard adjunctive treatment for patients with symp-
tomatic heart failure, significant left ventricular
(LV) systolic dysfunction, and delayed ventricular
conduction as manifest by an increased QRS dura-
tion (1,2). Despite the clear utility of CRT in
preventing death, reducing hospitalizations for
heart failure, and enhancing quality of life (3),
approximately one-third of CRT recipients do not
appear to derive a measurable benefit from this
therapy (4). The issue of nonresponse to CRT
is complicated by variability and marked
See page 1067
discrepancy in how response to CRT is defined in
various studies (5), the notion that patients who do
not clearly benefit, but do not worsen, after CRT
are considered as responders by some (4), and the
wide array of factors that are known to modify the
benefit from CRT in individual patients (6). None-
theless, the quest to better identify which patients
with heart failure are most likely and least likely to
benefit from CRT is a laudable goal given the cost,
complexity, and challenging long-term manage-
ment of these patients (7). Improved LV systolic
function and reduced LV systolic/diastolic dimen-
sions are often used as a measure of benefit for
CRT. These remodeling outcomes have the clear
advantage of being quantifiable, having reasonable
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ith long-term clinical outcomes in CRT recipients
8). However, hard clinical outcomes are desirable
iven the lack of a linear relationship between the
egree of favorable LV remodeling and long-term
linical outcome.
oo Little, Too Late?
s reflected in present guidelines for CRT (1,2),
any consider that patients with very advanced
eart failure symptoms, manifest as intractable
eart failure symptoms at rest (i.e., nonambulatory
ew York Heart Association functional class IV),
o not clearly benefit from CRT. While these
atients have a high risk of death, CRT is not
ndicated due to a lack of evidence regarding its
fficacy (i.e., their heart failure is too advanced and
RT is too little, too late). Furthermore, the
resence of advanced chronic kidney disease (9) and
ther comorbidities (10) are associated with poor
utcomes in CRT recipients. These patients were
argely excluded from the pivotal guidelines from
hich CRT indications were derived. Thus, the
ecision to implant a CRT system in such a patient
s driven by other factors, chiefly clinical judgment.
ence, it would seem reasonable to hypothesize that
atients with very severe LV systolic dysfunction,
anifest as severely compromised LV systolic func-
ion or marked LV dilation, may not benefit from
RT to the same extent as patients with more modest
mpairment in LV systolic function.
elationship Between Baseline LV Size and
unction and Response to CRT
here is both data supporting and data refuting the
otion that severely compromised LV systolic func-
ion is associated with a lesser response to CRT. In
ddition to the work cited in the paper by Carluccio
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1078et al. (11) in this issue of iJACC, Anto´nio et al. (12)
reported that patients with very favorable LV re-
modeling (i.e., CRT super-responders) had smaller
baseline LV end-diastolic and -systolic volumes
versus CRT recipients who experienced lesser ben-
efit. Likewise, the SCART (Selection of Candi-
dates for CRT) study investigators found that a
smaller baseline LV end-diastolic volume was asso-
ciated with a more favorable outcome after CRT
than were larger volumes. However, baseline LV
volumes were neither an overly sensitive nor specific
predictor of response to CRT, making the transla-
tion of these findings into clinical practice problem-
atic (13). In contradistinction, baseline LV ejection
fraction and differences in LV end-systolic and
-diastolic dimensions did not discriminate between
patients with better or poorer long-term clinical out-
comes in the pivotal CARE-HF (Cardiac Resynchro-
nization in Heart Failure) trial (14) or in another large
cohort study recently published by Shanks et al. (15).
urthermore, Vidal et al. (16) reported that larger, not
maller, LV end-diastolic volumes were predictive of a
reater likelihood of clinical response to CRT. Thus,
dditional data are needed to better understand the
elationship of baseline LV systolic function and
ubsequent response to CRT.
Should Baseline LV End Systolic Volume Index
be Used to Select Patients for CRT?
Carluccio et al. (11) report the outcomes of 78
patients with heart failure. LV parameters were
evaluated at baseline and again 6 to 8 months after
CRT using echocardiography. In addition to the
standard criteria for CRT implantation (symptom-
atic heart failure, severe LV systolic dysfunction,
and QRS duration 120 ms), patients in this study
ere required to have echocardiographic evidence
f mechanical dyssynchrony on tissue Doppler im-
ging. The majority of patients had a nonischemic
tiology of LV systolic dysfunction, the mean QRS
uration was 165 ms, and more than one-quarter of
atients had only minimally symptomatic heart
ailure. Patients were followed an average of 40
onths and the outcomes assessed were cardiac
eath and hospitalization for heart failure.
Change in LV ejection fraction at follow-up was
found to be independently and negatively associated
with the baseline LV end-systolic volume index
(p  0.001). Moreover, baseline LV end-systolic
volume index was identified as the most powerful
predictor of clinical events (hazard ratio 2.5 for
patients with LV end-systolic volume index values
above vs. below the study population median).Clinical events rates rose with increasing LV end-
systolic volume index. Patients with the lowest
values at baseline had an event rate that was
approximately one-fourth that of patients in highest
tertile of LV end-systolic volume index (6.3% vs.
23.8%). Patients in the middle tertile had interme-
diate event rates (10.2%).
The work by Carluccio et al. (11) adds important
information to the existing and discrepant results in
this area. As with all studies, there are limitations to
their work. In addition to the limitations noted by
the authors, drop out was significant, with 17 of 95
patients (18%) being excluded or lost to follow-up.
Moreover, important factors that may impact long-
term clinical outcome such as comorbid illness,
chronic kidney disease, along with the presence and
extent of myocardial scarring were not reported in
the paper or adjusted for in the statistical models.
Finally, the characteristics of patients in their study
differ from those of patients in recent pivotal clinical
trials (MADIT CRT [Multicenter Automatic De-
fibrillator Implantation Trial-Cardiac Resynchroni-
zation Therapy], RAFT [Resynchronization in
Ambulatory Heart Failure Trial]). Nonetheless, the
results presented add to a growing literature regard-
ing the relationship between severely compromised
LV systolic function and outcome after CRT.
Carluccio et al. (11) conclude that “despite the
presence of intraventricular dyssynchrony, patients
with more [a]dilated LV enjoy no or limited benefit
after implant.” Although this conclusion does re-
flect their results, there are a number of caveats that
need to be considered. It is difficult to tease out the
importance of individual predictors in a relatively
small study, such as that by Carluccio et al. (11).
This is particularly relevant when the population
includes a diverse range of patients. For example,
most patients had a nonischemic etiology of their
LV systolic dysfunction and it is unclear whether
their findings apply equally well to patients with an
ischemic etiology. The authors stress the value of
limiting enrollment to patients with documented
intraventricular dyssynchrony, but the role of echo-
cardiographic assessment of dyssynchrony is unclear
at present. Furthermore, more complex analysis of
LV and right ventricular geometry, LV systolic and
diastolic function, and the extent of myocardial
scarring may be helpful in identifying patients more
likely or less likely to respond to CRT. Finally, it is
premature to deprive a patient of a potentially
beneficial and life-extending therapy such as CRT
based on a single measure such as the LV end-
systolic volume index.
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1079It is undoubtedly true that some patients are too
sick to benefit from CRT. The challenge at present
is how do we reliably identify these patients? While
the work by Carluccio et al. (11) adds to a growing
literature in this area, it is too early to rely on LV
end-systolic volume index or any other parameter,
possibly aside from QRS duration, in guiding the
prescription or nonprescription of CRT. However,
the work by Carluccio et al. (11) will undoubtedly
aid in the design of larger, more definitive studiesP, et al. Agreement is poor among
current criteria used to define response
1
1
chrony. J Am Coll
4:1067–76.parameters can be prospectively assessed on a rep-
resentative population of CRT recipients in order to
determine which parameters or combination of
parameters can be used to identify, with certainty,
those patients more likely or less likely to benefit
from CRT.
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